Full text is available at the source.
Abstract
Comparison of kidney outcomes after initiation of GLP-1 receptor agonists or tirzepatide versus finerenone in adults with Type 2 diabetes and moderate chronic kidney disease is explored.
- The study focuses on patients with Type 2 diabetes and moderate chronic kidney disease.
- Kidney outcomes are compared between those treated with GLP-1 receptor agonists or tirzepatide and those receiving finerenone.
- Potential differences in kidney health may exist based on the type of medication initiated.
Simplified